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We examined the association of variation in the type 2 diabetes risk-conferring TCF7L2 gene with the risk of incident coronary
heart disease (CHD) among the lean, overweight, and obese members of the Atherosclerosis Risk in Communities (ARIC) Study
cohort. Cox proportional hazard regression analyses were performed using a general model, with the major homozygote as the
reference category. For 9,865 whites, a signiﬁcant increase in the risk of CHD was seen only among lean (BMI < 25kg/m2)
individuals homozygous for the T allele of the TCF7L2 rs7903146 gene risk variant (hazard ratio 1.42; 95% CI 1.03,1.97; P = .01).
No association was found among 3,631 blacks, regardless of BMI status. An attenuated hazard ratio was observed among the
nondiabetic ARIC cohort members. This study suggests that body mass modiﬁes the association of the TCF7L2 rs7903146 T allele
with CHD risk.
1.Introduction
Several studies have observed an association between the
transcription factor 7-like 2 (TCF7L2) gene and the risk
of diabetes [1]. In previous work, using data from the
Atherosclerosis Risk in Communities (ARIC) cohort, we
reported that the association between the TCF7L2 rs7903146
risk allele (T) and incidence of type 2 diabetes depended on
obesity status [2]. Those results were in agreement with data
from other studies which suggested a modulating eﬀect of
obesity status on the type 2 diabetes susceptibility in TCF7L2
rs7903146 risk allele carriers [3–5]. The modulating eﬀect of
obesity status on the association of genetic variants with the
risk of type 2 diabetes may in part be related to functional
characteristics. Gene variants which aﬀect beta cell function
and consequently insulin secretion have a more pronounced
eﬀect on the risk of type 2 diabetes among lean and normal
weight individuals, whereas gene variants aﬀecting insulin
activity at the peripheral cell level increase type 2 diabetes
susceptibility among the obese [4].
Individuals with diabetes are at increased risk of cardio-
vascular morbidity and mortality [6] but the relationship
between gene variants conferring type 2 diabetes suscepti-
bility and cardiovascular outcomes has not been suﬃciently2 Journal of Obesity
investigated. In this study, we examined whether obesity
aﬀects the association of the TCF7L2 rs7903146 gene variant
with the risk of incident coronary heart disease (CHD).
2. Methods and Procedures
The ARIC Study is a prospective cohort of 15,792 men and
women, aged 45–64 years at baseline (1987–1989), selected
as a probability sample from four US communities located
in North Carolina, Mississippi, Minnesota, and Maryland
[7] and followed through ongoing event surveillance,
annual follow-up interviews, and three triennial return
examinations.
In the present study, we excluded cohort participants
who reported race other than white or black (n = 48),
blacks from the Minnesota and Maryland centers (n = 55),
thosemissing TCF7L2 rs7903146 genotype information (n =
1050),thosewithprevalentCHDatbaseline(n = 766),those
missing baseline information on CHD (n = 344), and those
with body mass index (BMI) < 18.5( n = 144). The ﬁnal
number of cohort participants after exclusions was 13,496
(9,865 whites and 3,631 blacks), with average follow-up time
of 14.9 (±3.6) years.
Incident CHD, deﬁned as any deﬁnite or probable
hospitalized myocardial infarction (MI), deﬁnite fatal MI,
deﬁnite or possible fatal CHD, electrocardiographic (ECG)
MI (hospitalized occurrence), or coronary revascularization,
was ascertained through annual follow-up interviews con-
ducted from baseline examination through December 31,
2004 and reviewed by members of the ARIC Morbidity
and Mortality Classiﬁcation Committee, using published
criteria [7]. Identiﬁed myocardial infarction cases were
validated based on symptoms at presentation, peak cardiac
enzyme levels, and Minnesota Code values from three ECG
measurements. CHD deaths were ascertained based on death
certiﬁcates, informant interviews, physician questionnaires,
coroner reports, or hospital discharge summaries.
Physical examination of the cohort members and their
risk factor assessment were conducted during the base-
line visit [8]. Baseline diabetes was deﬁned as either
a self-reported physician’s diagnosis of diabetes, use of
hypoglycemic medications, nonfasting serum glucose levels
greater than 200mg/dL, or fasting (≥8 hr) serum glucose
levelequaltoorgreaterthan126mg/dL.BMIwasdetermined
based on height and weight measured at baseline. BMI
cutpoints were chosen ap r i o r iaccording to WHO guidelines
[9] for normal weight (18.5–24.99), overweight (25–29.99),
and obese (≥30). Cohort participants with BMI<18.5 were
excluded from analyses due to potential cachexia.
The rs7903146 genotype was determined at the ARIC
Study Central DNA Laboratory Health Science Center at
Houston, University of Texas School of Public Health, using
TaqMan assays (Applied Biosystems, Foster City, CA, USA).
Five percent of samples were regenotyped for quality control,
and 726 ARIC participants were genotyped in duplicate. The
percent agreement was 98%, and the simple κ coeﬃcient
was 0.97. Departure from Hardy-Weinberg equilibrium was
determined using the χ2 goodness-of-ﬁt test. We modeled
the association between the SNP and incident CHD using
a general model comparing individuals heterozygous (CT)
and homozygous (TT) for the minor T allele to individuals
homozygous(CC)forthemajorCallele.Thismodelimposes
no assumptions of linearity on the relationship between
the T allele and CHD across genotypes. Associations were
determined for each race group separately using Cox pro-
portional hazard regression (adjusted for gender and ARIC
study center), with age at time of event as the time variable.
We examined the eﬀect of BMI status on the association
of the TCF7L2 rs7903146 T allele with the risk of CHD
using likelihood ratio tests based on nested models with and
without the BMI∗risk allele interaction term. In separate
analyses, BMI was coded either as a continuous variable,
or as a dichotomous variable (cutpoint at 25kg/m2). We
used similar models of likelihood ratio tests to further
examine potential eﬀect modiﬁcation due to high-density
lipoprotein (HDL)-cholesterol, diabetes, cigarette smoking,
and hypertension.
3. Results
The minor allele (T) frequencies were 8.7% for the total
sample population, 8.9% among whites, and 8.3% among
blacks. The genotype distributions at rs7903146 conformed
to Hardy-Weinberg equilibrium in the entire sample and
within race strata. Baseline characteristics of the sample,
stratiﬁed by race, are presented in Table 1. Mean BMI values
diﬀered by genotype in the total sample (P = .03), but not
within race strata (whites P = .11; blacks P = .28).
Although we observed no signiﬁcant association of the
rs7903146 TCF7L2 gene variant with CHD overall (Table 2,
P = .22), we observed that BMI, coded as a continuous
variable, modiﬁed the association of the rs7903146 TCF7L2
gene variant with the relative hazard of CHD among whites
(Pinteraction <. 01), but not among blacks (Pinteraction = .45). A
similar pattern of eﬀect modiﬁcation was observed with BMI
coded as a dichotomous variable using the clinically deﬁned
overweight cutpoint (25kg/m2).
A statistically signiﬁcant association of the TCF7L2
rs7903146 gene variant with the relative hazard of CHD
was observed only among persons with BMI < 25kg/m2
(0020HR 1.40 (95% CI 1.04, 1.88)) (Table 2). This associa-
tion was signiﬁcant among whites (HR 1.42 (95% CI 1.03,
1.97)), but not among blacks (HR 1.26 (95% CI 0.58, 2.71)).
A similar pattern was observed for the association of the
rs7903146riskallelewithCHDacrossgender-speciﬁctertiles
of waist circumference and subscapular skinfold thickness.
We did not observe a statistically signiﬁcant eﬀect of
diabetes on the association of the TCF7L2 rs7903146 gene
variant with the risk of CHD (Pinteraction = .40). Limiting
analysis to lean and normal weight (BMI < 25kg/m2)c o h o r t
members who were free of diabetes resulted in a relative
hazard of CHD among the carriers of the risk genotype of
1.33 (95% CI 0.94, 1.88) for the total sample and 1.36 (95%
CI 0.94, 1.96) among whites. When assuming the recessive
mode of inheritance (CC and CT alleles as the referent), we
found that the hazard ratio of CHD among lean and normalJournal of Obesity 3
Table 1: Baseline characteristics of the sample population (whites and blacks combined) according to TCF7L2 genotype, the ARIC study
cohort.
Characteristic CC CT TT
n = 6,736 n = 5,583 n = 1,177
Age (years) 54.0 (5.7) 53.9 (5.8) 54.1 (5.8)
BMI (kg/m2) 27.8 (5.4) 27.6 (5.3) 27.5 (4.9)
HDL-cholesterol (mmol/L) 1.4 (0.4) 1.4 (0.4) 1.3 (0.4)
Fasting glucose (mmol/L) 6.0 (2.2) 6.1 (2.2) 6.2 (2.3)
Gender (% Male) 42.8 43.9 44.8
Race (% Black) 26.9 27.2 25.7
Diabetes (%) 9.6 12.5 14.5
Hypertension (%) 33.7 34.6 31.1
Ever smoker (%) 56.5 57.4 58.6
∗diﬀerences across genotype strata were signiﬁcant at α = 0.05 only for BMI (P = .03), diabetes (P<. 01), and fasting glucose (P<. 01).
Table 2: Association of the TT and CT genotypes of the TCF7L2 rs7903146 gene variant with the incidence of coronary heart disease in
categories of BMI. Cox proportional hazard analyses were performed with age at time of event as the time variable and adjustment for
gender and ARIC study center. For the total sample and in race strata, the referent category was individuals with BMI < 25kg/m2 carrying
the CC genotype of the TCF7L2 rs7903146 gene variant.
Total sample (n = 13,496) Whites (n = 9,865) Blacks (n = 3,631)
CC CT TT CC CT TT CC CT TT
(n = 6,736) (n = 5,583) (n = 1,177) (n = 4,927) (n = 4,063) (n = 875) (n = 1,809) (n = 1,520) (n = 302)
Events 883 717 172 691 551 129 192 166 43
p-years 100,435 82,899 17,384 74,421 61,053 13,112 26,015 21,846 4,272
HR (95% CI) 1.02 1.11 1.00 1.07 1.08 1.24
1.00 (0.92, 1.12) (0.94, 1.31) 1.00 (0.89, 1.11) (0.89, 1.30) 1.00 (0.88, 1.33) (0.89, 1.72)
BMI categories:
BMI < 25
(n = 4,476)
Events 210 159 55 175 124 47 35 35 8
p-years 33,083 28,2006 6,033 27,850 23,577 5,134 5,232 4,629 900
HR (95% CI) 0.90 1.40 0.82 1.42 1.31 1.26
1.00 (0.74, 1.11) (1.04, 1.88) 1.00 (0.65, 1.04) (1.03, 1.97) 1.00 (0.82, 2.09) (0.58, 2.71)
BMI 25–30
(n = 5,325)
Events 394 320 67 324 260 52 70 60 15
p-years 39,309 32,918 6,989 29,446 24,454 5,399 9,862 8,464 1,590
HR (95% CI) 1.33 1.31 1.28 1.31 1.28 1.18 1.22 1.25 1.55
(1.12, 1.57) (1.10, 1.56) (0.97, 1.69) (1.09, 1.58) (1.06, 1.56) (0.86, 1.61) (0.81, 1.83) (0.82, 1.89) (0.85, 2.85)
BMI ≥30
(n = 3,695)
Events 279 238 50 192 167 30 87 71 20
p-years 28,045 21,776 4,361 17,124 13,023 2,579 10,920 8,753 1,782
HR (95% CI) 1.61 1.85 1.89 1.56 1.95 1.71 1.57 1.53 2.02
(0.35, 1.93) (1.53, 2.23) (1.39, 2.57) (0.27, 1.91) (1.58, 2.41) (1.16, 2.53) (1.06, 2.34) (1.01, 2.30) (1.16, 3.51)
weight whites with diabetes was 2.13 (95% CI 1.00, 4.55)
as compared to the hazard ratio of CHD among lean and
normal weight whites without diabetes (HR 1.35 (95% CI
0.96, 1.91)).
Eﬀect measure modiﬁcation of the association of the
TCF7L2 rs7903146 gene variant with the risk of CHD is
stronger for nonfatal MI as compared to total CHD, which
in this study included, in addition to myocardial infarction,
fatal CHD, silent MI, and coronary procedures. The hazard
ratio for the association of this polymorphism with the risk
of myocardial infarction among the lean and normal weight
ARIC cohort participants was 1.72 (95% CI 1.14, 2.60).4 Journal of Obesity
4. Discussion
Our results suggest that among individuals homozygous
for the T allele of the TCF7L2 rs7903146 gene variant, the
relative hazard of coronary heart disease may be modestly
increasedamongtheleanandnormalweightindividuals,but
not among the overweight or the obese. We observed this
association in the total sample and among whites; however,
we did not observe any pattern of association among the
blacks of this study, possibly due to insuﬃcient statistical
power; we calculated that we had only 10% power to detect a
hazard ratio of 1.6 among blacks.
This study expands on that of Bielinski et al. [10], in
which the authors examined the association of variants of
the TCF7L2 gene with the risk of coronary heart disease
and found a signiﬁcant level of association only among
whites with diabetes and only with additional adjustment
for BMI. The present ﬁnding of a modest association of a
variant in the TCF7L2 gene with increased relative hazard of
coronary heart disease is consistent with the greater risk of
cardiovascular disease in those with, or at risk of diabetes.
Onecanspeculatebasedonthis,thatageneticpredisposition
towards development of diabetes may carry an increased risk
of coronary heart disease. It is diﬃcult in population studies
to answer the question to what degree TCF7L2 inﬂuences
cardiovascular risk independently or through diabetes. We
attempted to address this question by stratifying our analyses
by diabetes status and by increasing the power of analysis
with the assumption of recessive mode of inheritance for this
gene. However, such adjustment strategies are crude and our
sample size was too small to disentangle the possible role
of diabetes in the association of TCF7L2 with CHD in this
population.
We examined the association of the TCF7L2 gene variant
with the risk of CHD across strata of tertiles of waist
circumference and subscapular skinfold thickness, which
are often used as more direct measures of visceral or
subcutaneous adipose tissue. Although the associations were
weakerthaninstrataofBMI,thepatternsofassociationwere
similar, suggesting that the association is related to overall
adiposity rather than more speciﬁcally to subcutaneous or
visceral fat. If replicated in other studies, this observation
would be consistent with results obtained from studies of
the association of genetic variation in the TCF7L2 gene
and diabetes [4]. The TCF7L2 gene is part of the Wnt
signaling pathway [11] a critical pathway in cell development
which regulates, among others, the activity of glucagon-
like peptide-1 (GLP-1) [12]. Presence of genetic variants in
the TCF7L2 gene is associated with decreased insulin levels
[13], an eﬀect that may be a consequence of a decrease
in stimulation of insulin release by GLP-1. This is a direct
eﬀect on beta cell function that is independent of obesity-
induced insulin resistance and subsequent impaired insulin
secretion and gluconeogenesis. Impaired insulin secretion
and abnormal plasma glucose levels, observed in diabetes,
represent dysregulation of multiple metabolic pathways. It
is thus possible that the mechanism of diabetes is diﬀerent
in lean as compared to obese individuals, in whom inputs
from other metabolic dysfunctions contribute additional
impairment. The rs7903146 SNP is not in the coding region
of the TCF7L2 gene therefore the modality by which it
imparts increased susceptibility to type 2 diabetes is diﬃcult
to attribute. It is equally diﬃcult to identify the speciﬁc
function of obesity status in the association of the TCF7L2
genewithincidenceofdiabetes.TheTCF7L2factorcanaﬀect
expression of the Wnt signaling pathway thus leading to
increased adipogenesis [14] and in that way may contribute
to a milieu conducive to the development of diabetes.
The above mentioned mechanisms, suggestive of a
pleiotropic eﬀect of the TCF7L2 gene, may diﬀerentially
contribute to increased risk of coronary heart disease.
Replication of our results in other, preferably larger, cohorts
would broaden the understanding of the increased risk of
cardiovascular disease in individuals with diabetes and those
at increased risk of diabetes.
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